Most cancer immunotherapy efforts, including immune checkpoint inhibitors (e.g., anti–programmed cell death protein 1 [PD1] antibodies), are aimed at maximizing the effect of tumor-infiltrating lymphocytes (TILs) through different approaches [2–5]. The gene discussed is PDCD1; the disease is cancer.